Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Optimized Radiochemical Applications, commonly known as ORA, is a Belgium-based radiochemistry and nuclear medicine tools company focused on automated synthesizers for PET and other radiopharmaceutical production. The company develops, designs, manufactures, and supplies multi-purpose radiochemistry modules and related software under the NEPTIS brand for research use, clinical trials, and commercial clinical production. ORA's open-platform systems are used by academic centers, radiopharmacies, and commercial producers to create individualized radiotracer synthesis workflows and support regulatory-compliant manufacturing. The company also provides accessories, spare parts, software, and radiochemistry-related consulting and innovation support. ORA was acquired by Ion Beam Applications in December 2025 but appears to continue operating as an active business within the IBA group.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Optimized Radiochemical Applications.